Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991

Up to 30% of patients who undergo radiation for intermediate- or high-risk localized prostate cancer relapse biochemically within 5 years. We assessed if biochemical disease-free survival (DFS) is improved by adding 6 months of androgen suppression (AS; two injections of every-3-months depot of lute...

Celý popis

Podrobná bibliografia

Vydané v:	Journal of clinical oncology Ročník 34; číslo 15; s. 1748
Hlavní autori:	Bolla, Michel, Maingon, Philippe, Carrie, Christian, Villa, Salvador, Kitsios, Petros, Poortmans, Philip M P, Sundar, Santhanam, van der Steen-Banasik, Elzbieta M, Armstrong, John, Bosset, Jean-François, Herrera, Fernanda G, Pieters, Bradley, Slot, Annerie, Bahl, Amit, Ben-Yosef, Rahamim, Boehmer, Dirk, Scrase, Christopher, Renard, Laurette, Shash, Emad, Coens, Corneel, van den Bergh, Alphonsus C M, Collette, Laurence
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 20.05.2016
Predmet:	Adult Aged Aged, 80 and over Androgen Antagonists - therapeutic use Combined Modality Therapy Humans Male Middle Aged Prostate-Specific Antigen - blood Prostatic Neoplasms - mortality Prostatic Neoplasms - therapy Radiotherapy Dosage
ISSN:	1527-7755, 1527-7755
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!